Compare FNKO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNKO | SPRO |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.5M | 135.5M |
| IPO Year | 2017 | 2017 |
| Metric | FNKO | SPRO |
|---|---|---|
| Price | $4.39 | $2.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 487.5K | 419.9K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ 0.15 |
| Revenue | ★ $908,209,000.00 | $66,802,000.00 |
| Revenue This Year | $4.42 | N/A |
| Revenue Next Year | $6.50 | $300.00 |
| P/E Ratio | ★ N/A | $16.10 |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $2.22 | $0.58 |
| 52 Week High | $5.64 | $3.09 |
| Indicator | FNKO | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 46.37 |
| Support Level | $4.23 | $2.15 |
| Resistance Level | $4.62 | $2.70 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 41.98 | 23.30 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.